Artículos por temáticas

Molecular Imaging of Extrapyramidal Movement Disorders.

Frey KA.

Semin Nucl Med. 2017 Jan;47(1):18-30. doi: 10.1053/j.semnuclmed.2016.09.007. Review.

Clinical decision-making in functional and hyperkinetic movement disorders.

van der Salm SM, van Rootselaar AF, Cath DC, de Haan RJ, Koelman JH, Tijssen MA.

Neurology. 2017 Jan 10;88(2):118-123. doi: 10.1212/WNL.0000000000003479.

Hyperkinetic psychogenic movement disorders remain a diagnosis at first sight.

Hedera P, Gambardella A.

Neurology. 2017 Jan 10;88(2):114-115. doi: 10.1212/WNL.0000000000003494. No abstract available.

Psychogenic Movement Disorders and Dopamine Transporter Scans: Still a Clinical Diagnosis?

Moguel-Cobos G, Maroney Z, Erickson JM, Tröster AI, Quinn DK.

Psychosomatics. 2017 Jan - Feb;58(1):83-89. doi: 10.1016/j.psym.2016.08.009. No abstract available.

Molecular Imaging and Precision Medicine in Dementia and Movement Disorders.

Mallik AK, Drzezga A, Minoshima S.

PET Clin. 2017 Jan;12(1):119-136. doi: 10.1016/j.cpet.2016.08.003. Review.

Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.

Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Chung TM, Ebke M, Jacinto LJ, Kaji R, Koçer S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoe

J Neurol. 2017 Jan;264(1):112-120. doi: 10.1007/s00415-016-8304-z.

Intraoperative electrocorticography for physiological research in movement disorders: principles and experience in 200 cases.

Panov F, Levin E, de Hemptinne C, Swann NC, Qasim S, Miocinovic S, Ostrem JL, Starr PA.

J Neurosurg. 2017 Jan;126(1):122-131. doi: 10.3171/2015.11.JNS151341.

Minimally invasive motor cortex stimulation for Parkinson's disease.

Lavano A, Guzzi G, DE Rose M, Romano M, Della Torre A, Vescio G, Deodato F, Lavano F, Volpentesta G.

J Neurosurg Sci. 2017 Feb;61(1):77-87.

Mechanisms of Parkinson's Disease: Lessons from Drosophila.

Hewitt VL, Whitworth AJ.

Curr Top Dev Biol. 2017;121:173-200. doi: 10.1016/bs.ctdb.2016.07.005.

Validation of the Italian version of the Non Motor Symptoms Scale for Parkinson's disease.

Cova I, Di Battista ME, Vanacore N, Papi CP, Alampi G, Rubino A, Valente M, Meco G, Contri P, Di Pucchio A, Lacorte E, Priori A, Mariani C, Pomati S.

Parkinsonism Relat Disord. 2017 Jan;34:38-42. doi: 10.1016/j.parkreldis.2016.10.020.

Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease.

Baba T, Hosokai Y, Nishio Y, Kikuchi A, Hirayama K, Suzuki K, Hasegawa T, Aoki M, Takeda A, Mori E.

J Neurol Sci. 2017 Jan 15;372:288-293. doi: 10.1016/j.jns.2016.11.068.

Apomorphine pump in advanced Parkinson's disease: Effects on motor and nonmotor symptoms with brain metabolism correlations.

Auffret M, Le Jeune F, Maurus A, Drapier S, Houvenaghel JF, Robert GH, Sauleau P, Vérin M.

J Neurol Sci. 2017 Jan 15;372:279-287. doi: 10.1016/j.jns.2016.11.080.

Decision-making performance in Parkinson's disease correlates with lateral orbitofrontal volume.

Kobayakawa M, Tsuruya N, Kawamura M.

J Neurol Sci. 2017 Jan 15;372:232-238. doi: 10.1016/j.jns.2016.11.046.

Lower body mass index is associated with orthostatic hypotension in Parkinson's disease.

Nakamura T, Suzuki M, Ueda M, Hirayama M, Katsuno M.

J Neurol Sci. 2017 Jan 15;372:14-18. doi: 10.1016/j.jns.2016.11.027.

Corrigendum to Review of Amyotrophic Lateral Sclerosis, Parkinson's and Alzheimer's diseases helps further define proteomic events of the novel paradigm for Alzheimer's with metals as primary disease cause [Med. Hypotheses 85 (2015) 779-790].

Cavaleri F.

Med Hypotheses. 2017 Jan;98:5. doi: 10.1016/j.mehy.2016.10.022. No abstract available.